MINNEAPOLIS--(BUSINESS WIRE)--NMDP BioTherapies℠ (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, announced today it is relaunching an improved suite of premium services for developers of autologous cell and gene therapies in response to demand from its customer base of allogeneic services..

明尼阿波利斯--（商业新闻短讯）--细胞和基因治疗开发支持的领导者NMDP BioTherapies℠（以前称为Be the Match BioTherapies）今天宣布，它正在为自体细胞和基因治疗的开发者重新推出一套改进的优质服务，以响应其同种异体服务客户群的需求。。

“Our customers have continued to tell us that the regulatory, industry and operational complexities inherent in autologous sourcing and delivery are onerous – especially in a relatively nascent cell and gene therapy industry,” Tom Hochuli, CEO and President of NMDP BioTherapies, said. “We reimagined a premium level of end-to-end support, to continually improve how we advance comprehensive autologous cell therapy development support that serves our customers’ patient needs.”.

NMDP BioTherapies首席执行官兼总裁汤姆·霍丘利（TomHochuli）表示：“我们的客户不断告诉我们，自体采购和交付固有的监管、行业和运营复杂性非常繁重，尤其是在一个相对新兴的细胞和基因治疗行业。”。。

Next Generation Advancements in Autologous Cell Therapy Development

自体细胞疗法发展的下一代进展

These best-in-class offerings are designed to ensure consistency in the collection, packaging and shipping of critical autologous starting materials and manufactured biotech products. This slate of premium services support NMDP BioTherapies’ apheresis network and managed logistics services, including apheresis center (AC) qualification and onboarding, apheresis network management, as well as 24/7/365 logistics and supply chain support, featuring client-specific dedicated teams.

这些一流的产品旨在确保关键自体原料和生物技术产品的收集，包装和运输的一致性。这一系列优质服务支持NMDP BioTherapies的单采血液网络和管理的物流服务，包括单采血液中心（AC）资格认证和登机、单采血液网络管理，以及365年7月24日的物流和供应链支持，以客户特定的专业团队为特色。

NMDP BioTherapies has onboarded, trained, or managed over 165 ACs globally for clients developing autologous cell and gene therapies and has brought to bear its expertise in handling global logistics for autologous developers since its inception in 2016..

NMDP BioTherapies自2016年成立以来，已在全球范围内为开发自体细胞和基因疗法的客户提供了超过165个AC的培训或管理，并为自体开发者提供了处理全球物流的专业知识。。

“Our suite of services balances two critical – and sometimes – opposing forces,” said Jeni Newman, senior director of operations at NMDP BioTherapies. “Providing premier apheresis network support and managed logistics services is critical to cell and gene developers as well as patients in need, but those services need to be delivered in a way that minimizes cost.”.

NMDP BioTherapies运营高级总监杰尼·纽曼（JeniNewman）表示：“我们的服务套件平衡了两股关键的、有时甚至是对立的力量。”。“提供卓越的单采血液网络支持和管理物流服务对于细胞和基因开发人员以及有需要的患者至关重要，但这些服务需要以最小化成本的方式提供。”。

NMDP BioTherapies has supported organizations creating next-generation autologous cell and gene therapies since 2016, leveraging NMDP’s experience building and managing a national apheresis network and orchestrating time sensitive delivery of over 130,000 life-saving cell therapies over the past 35 years.

自2016年以来，NMDP BioTherapies一直支持创建下一代自体细胞和基因疗法的组织，利用NMDP在建立和管理国家单采血液网络方面的经验，并在过去35年中协调了超过130000种救生细胞疗法的时间敏感交付。

With this expertise, NMDP BioTherapies is uniquely able to help its clients overcome challenges scaling collection networks and managing complex logistics to deliver ever-increasing volumes of autologous cell and gene therapies safely, reliably, and cost effectively..

凭借这一专业知识，NMDP BioTherapies能够帮助其客户克服挑战，扩大收集网络并管理复杂的物流，以安全、可靠、经济高效地提供不断增加的自体细胞和基因疗法。。

Additionally, as part of the reintroduction of these services to cell therapy developers, members of the NMDP BioTherapies team will be attending the 2024 Cell & Gene Meeting on the Mesa, which is taking place from October 7 to 9 in Phoenix, AZ.

此外，作为向细胞疗法开发人员重新引入这些服务的一部分，NMDP生物疗法团队的成员将参加10月7日至9日在亚利桑那州凤凰城举行的2024年Mesa细胞与基因会议。

About NMDP BioTherapies

关于NMDP生物疗法

NMDP BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of NMDP℠ and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization designs solutions that advance the development of cell and gene therapies across the globe..

NMDP BioTherapies是唯一一家提供可定制服务以支持端到端细胞治疗供应链的细胞和基因治疗解决方案提供商。该组织凭借NMDP的行业领先经验以及与CIBMTR®（国际血液和骨髓移植研究中心®）的研究合作伙伴关系，设计了推动全球细胞和基因疗法发展的解决方案。。

NMDP BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the NMDP Registry℠, the world’s most diverse registry of more than 7 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection, and transplant centers worldwide, the organization develops, onboards, trains, and manages expansive collection networks to advance cell therapies.

NMDP BioTherapies致力于通过从NMDP Registry℠提供高质量的细胞源材料来加速患者获得挽救生命的细胞和基因疗法，NMDP Registry是世界上最多样化的注册中心，有700多万潜在的造血干细胞捐献者。通过与世界各地的单采血液、骨髓采集和移植中心建立关系，该组织开发、部署、培训和管理广泛的采集网络，以推进细胞疗法。

NMDP BioTherapies uses a proven infrastructure consisting of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to successfully transport and deliver regulatory-compliant life-saving therapies across the globe. Through the CIBMTR, NMDP extends services beyond the cell therapy supply chain to include long-term follow-up tracking for FDA-approved CAR-T therapies..

NMDP BioTherapies使用由法规遵从性和管理物流专家以及细胞治疗供应链案例管理人员组成的经验证的基础设施，在全球范围内成功运输和提供符合法规的救生疗法。通过CIBMTR，NMDP将服务扩展到细胞疗法供应链之外，包括对FDA批准的CAR-T疗法进行长期跟踪。。

For more information, follow NMDP BioTherapies on LinkedIn or Twitter.

有关更多信息，请在LinkedIn或Twitter上关注NMDP生物疗法。